Applied Molecular Transport Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Shawn M. Cross
- Full Time Employees
- 13
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 450 East Jamie Court South San Francisco CA United States of America 94080
- IPO Date
- Jun 5, 2020
- CIK
- 0001801777
- Website
- appliedmt.com
- Similar Companies
- Business
- Applied Molecular Transport Inc. (AMTI) is a clinical-stage biopharmaceutical company that leverages a proprietary technology platform to design and develop oral biologic product candidates for autoimmune, inflammatory, metabolic, and other diseases. The company offers a pipeline including AMT-101, a gastrointestinal-selective oral fusion of recombinant human interleukin-10 in Phase II trials for chronic pouchitis and rheumatoid arthritis; AMT-126, a gastrointestinal-selective oral fusion of interleukin-22 in Phase I trials for intestinal epithelium barrier defects; and additional oral and respiratory modalities such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Founded in 2010 and formerly headquartered in South San Francisco, California, with operations in the United States, AMTI completed a merger with Cyclo Therapeutics Inc. in December 2023, operating thereafter as a subsidiary headquartered in Gainesville, Florida.
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI
Applied Molecular Transport Reports Third Quarter 2023 Financial Results
APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
Applied Molecular Transport Reports Second Quarter 2023 Financial Results
What Makes Applied Molecular Transport Inc. (AMTI) a New Buy Stock
Is Applied Molecular Transport (AMTI) Stock Outpacing Its Medical Peers This Year?
Applied Molecular Transport to Present at Upcoming November Investor Conferences
Zephyr AI Announces Additions to the Board of Directors
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Applied Molecular Transport Inc. with Losses of $100,000 to Contact the Firm
Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
VMware Advances Its Anywhere Workspace Platform To Enable Intelligent, Proactive Security for All Employee Devices
Applied Molecular Cuts Its Workforce By 40%, Pauses Early-Stage Research Programs
Applied Molecular Transport to Present at BofA Securities 2022 Healthcare Conference
Applied Molecular Transport to Report Top-line Phase 2 Results from FILLMORE Trial of Oral AMT-101 in Patients with Chronic Pouchitis
Applied Molecular Transport to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference
Applied Molecular Transport to Host Virtual Research & Development Day on October 15, 2021
Applied Molecular Transport Announces Upcoming Investor Events in September and October